DE602005020667D1 - Verwendung von 2-phenyl-1,2-ethanediol-(di)carbamaten zur behandlung von epileptogenese - Google Patents

Verwendung von 2-phenyl-1,2-ethanediol-(di)carbamaten zur behandlung von epileptogenese

Info

Publication number
DE602005020667D1
DE602005020667D1 DE602005020667T DE602005020667T DE602005020667D1 DE 602005020667 D1 DE602005020667 D1 DE 602005020667D1 DE 602005020667 T DE602005020667 T DE 602005020667T DE 602005020667 T DE602005020667 T DE 602005020667T DE 602005020667 D1 DE602005020667 D1 DE 602005020667D1
Authority
DE
Germany
Prior art keywords
phenyl
group
alkyl
epileptogenesis
ethanediol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005020667T
Other languages
English (en)
Inventor
Yong Moon Choi
Robert Gordon
Gerald P Novak
Carlos R Plata-Salaman
Roy E Twyman
H Steve White
Boyu Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE602005020667D1 publication Critical patent/DE602005020667D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005020667T 2004-09-16 2005-09-15 Verwendung von 2-phenyl-1,2-ethanediol-(di)carbamaten zur behandlung von epileptogenese Active DE602005020667D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61027604P 2004-09-16 2004-09-16
US69862505P 2005-07-12 2005-07-12
US70724205P 2005-08-11 2005-08-11
PCT/US2005/032861 WO2006033947A2 (en) 2004-09-16 2005-09-15 Use of 2-phenyl-1, 2-ethanediol- (di) carbamates for treating epileptogenesis and epilepsy

Publications (1)

Publication Number Publication Date
DE602005020667D1 true DE602005020667D1 (de) 2010-05-27

Family

ID=36087909

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005020667T Active DE602005020667D1 (de) 2004-09-16 2005-09-15 Verwendung von 2-phenyl-1,2-ethanediol-(di)carbamaten zur behandlung von epileptogenese

Country Status (23)

Country Link
US (2) US20060194873A1 (de)
JP (1) JP2008513466A (de)
KR (1) KR20070057939A (de)
CN (1) CN101056629B (de)
AT (1) ATE464044T1 (de)
AU (1) AU2005287174B2 (de)
BR (1) BRPI0515374A (de)
CA (1) CA2580640A1 (de)
CO (1) CO6382111A2 (de)
CR (1) CR9053A (de)
DE (1) DE602005020667D1 (de)
DK (1) DK1809273T3 (de)
EA (1) EA200700642A1 (de)
ES (1) ES2342185T3 (de)
HK (1) HK1105583A1 (de)
HR (1) HRP20100304T1 (de)
IL (1) IL181910A0 (de)
MX (1) MX2007003278A (de)
NO (1) NO20071921L (de)
NZ (1) NZ553813A (de)
PT (1) PT1809273E (de)
RS (1) RS51269B (de)
WO (1) WO2006033947A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517407A (en) * 1999-08-10 2003-10-31 Uab Research Foundation Use of GABA agonists for treatment of spastic disorders, convulsions, and epilepsy
AU2005295787A1 (en) * 2004-10-15 2006-04-27 Janssen Pharmaceutica, N.V. Carbamate compounds for use in treating neurodegenerative disorders
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
JP5443981B2 (ja) 2006-06-15 2014-03-19 ウーツェーベー ファルマ ゲーエムベーハー 相乗的抗痙攣効果を有する医薬組成物
EA200970355A1 (ru) * 2006-10-06 2009-12-30 Янссен Фармацевтика Нв Новый кристалл (s)-(+)-2-(2-хлорфенил)-2-гидроксиэтилкарбамата
MX2009004798A (es) * 2006-10-31 2009-08-12 Janssen Pharmaceutica Nv Tratamiento de los trastornos generalizados del desarrollo.
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
EP2797881B1 (de) * 2011-12-27 2018-11-14 Bio-Pharm Solutions Co., Ltd. Phenylalkylcarbamat-derivatverbindung und diese enthaltende pharmazeutische zusammensetzung
KR101717872B1 (ko) * 2013-03-12 2017-03-17 (주)바이오팜솔루션즈 소아 간질 및 간질-관련 증후군의 예방 또는 치료용 페닐카바메이트 화합물
EP2970109A4 (de) * 2013-03-12 2017-01-18 Bio-Pharm Solutions Co., Ltd. Phenylcarbamatverbindung und neuroprotektionszusammensetzung damit
JP6807941B2 (ja) * 2016-02-29 2021-01-06 バイオ−ファーム ソリューションズ カンパニー リミテッド スルファメート誘導体化合物、その製造方法および用途
CN106053510A (zh) * 2016-05-16 2016-10-26 山东省分析测试中心 一种基于氢核磁共振快速测定普瑞巴林原料药纯度的方法
KR102421006B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US20010034365A1 (en) * 1996-01-16 2001-10-25 Choi Yong Moon Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
WO1997045160A1 (en) * 1996-05-31 1997-12-04 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
PT1156798E (pt) * 1999-02-09 2003-11-28 Univ Virginia Compostos derivados de felbamato
EP1196156B1 (de) * 1999-07-26 2008-04-30 SK Holdings Co., Ltd. Transnasale anticonvulsive zusammensetzungen
DK1368021T3 (da) * 2001-02-27 2008-02-11 Ortho Mcneil Pharm Inc Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af bipolær sygdom
NZ527988A (en) * 2001-02-27 2006-01-27 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating bipolar disorder
CN1235579C (zh) * 2001-02-27 2006-01-11 奥索-麦克尼尔药品公司 用于预防或治疗神经变性疾病的氨基甲酸酯化合物

Also Published As

Publication number Publication date
CO6382111A2 (es) 2012-02-15
NO20071921L (no) 2007-06-12
AU2005287174B2 (en) 2012-01-12
ATE464044T1 (de) 2010-04-15
MX2007003278A (es) 2007-10-08
ES2342185T3 (es) 2010-07-02
HRP20100304T1 (hr) 2010-09-30
CR9053A (es) 2009-10-30
JP2008513466A (ja) 2008-05-01
WO2006033947A3 (en) 2006-06-29
RS51269B (sr) 2010-12-31
AU2005287174A1 (en) 2006-03-30
CN101056629B (zh) 2012-01-11
IL181910A0 (en) 2007-07-04
CN101056629A (zh) 2007-10-17
CA2580640A1 (en) 2006-03-30
EA200700642A1 (ru) 2007-10-26
DK1809273T3 (da) 2010-08-02
KR20070057939A (ko) 2007-06-07
US20060194873A1 (en) 2006-08-31
NZ553813A (en) 2010-09-30
US20110152362A1 (en) 2011-06-23
WO2006033947A2 (en) 2006-03-30
PT1809273E (pt) 2010-05-10
BRPI0515374A (pt) 2008-07-22
HK1105583A1 (en) 2008-02-22

Similar Documents

Publication Publication Date Title
DE602005020667D1 (de) Verwendung von 2-phenyl-1,2-ethanediol-(di)carbamaten zur behandlung von epileptogenese
EA200800294A1 (ru) Способы нейропротекции
TW200744575A (en) Methods of treating epileptogenesis
ATE538784T1 (de) Verfahren zur behandlung von substanzbedingten erkrankungen
MY138156A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
YU67703A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
DE60210976D1 (de) Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung
RS67603A (en) Carbamate compounds for use in the treatment of pain
DE60210960D1 (de) Carbamat-verbindungen zur prävention oder behandlung von angstzuständen
MX2009004553A (es) Metodos para el tratamiento de trastornos cocleares y vestibulares.
RS67503A (en) Carbamate compounds for use in preventing of treating psychotic disorders
ATE435014T1 (de) Carbamate verbindungen zur vorbeugung oder behandlung von neuropathischen schmerzen
TW200701978A (en) Methods of treating epileptogenesis and epilepsy
CY1110672T1 (el) Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1809273

Country of ref document: EP

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN, DE